esomeprazole + BMS-275183

Esomeprazole + BMS-275183 is a combination of two active pharmaceutical ingredients: esomeprazole, a proton pump inhibitor, and BMS-275183, an oral taxane analogue. - **Esomeprazole** reduces gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system (proton pump) in gastric parietal cells; it is primarily used for acid-reflux disorders such as erosive esophagitis, GERD, peptic ulcer disease, and prevention of gastrointestinal bleeding with NSAID use[1]. - **BMS-275183** is an orally active taxane and a C-4 methyl carbonate analogue of paclitaxel with antitumor activity. It acts by stabilizing microtubules, thereby inhibiting cell division; it is under investigation for treatment of solid tumors, especially non-small cell lung cancer and other malignancies[2][4][8]. - No evidence was found of the existence or clinical use of this combination (as a fixed-dose or investigated regimen), nor is it reported under a combination brand. The mechanistic rationale for their co-administration would be gastric protection (esomeprazole) alongside chemotherapy (BMS-275183), but there is no documentation of this specific combination in the biomedical literature.

Other names

esomeprazole + BMS-275183